These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1450 related items for PubMed ID: 30747897

  • 1. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S.
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [Abstract] [Full Text] [Related]

  • 5. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [Abstract] [Full Text] [Related]

  • 6. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND, STAMPEDE investigators.
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F, Fizazi K.
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [Abstract] [Full Text] [Related]

  • 13. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ, Oestreich MC, Brown SJ, Gupta S, Konety BR, Dahm P, Kunath F.
    Cochrane Database Syst Rev; 2020 Dec 12; 12(12):CD013245. PubMed ID: 33314020
    [Abstract] [Full Text] [Related]

  • 14. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG, Agarwal N, Araujo JC, Sonpavde G.
    Eur Urol Focus; 2019 May 12; 5(3):369-380. PubMed ID: 29275145
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov 12; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 18. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A, PEACE-1 investigators.
    Lancet; 2022 Apr 30; 399(10336):1695-1707. PubMed ID: 35405085
    [Abstract] [Full Text] [Related]

  • 19. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
    Weiner AB, Nettey OS, Morgans AK.
    Curr Treat Options Oncol; 2019 Jul 09; 20(9):69. PubMed ID: 31286275
    [Abstract] [Full Text] [Related]

  • 20. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
    Thomas C, Ohlmann CH.
    Urologe A; 2020 Jun 09; 59(6):665-672. PubMed ID: 32274544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.